Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma confined to the brain, spinal cord, leptomeninges and eyes. Its pathogenesis is complex, involving ...

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The ...

Patients with primary central nervous system lymphoma aged 70 and older may be eligible for Imbruvica as maintenance treatment. Using Imbruvica (ibrutinib) as maintenance treatment may provide a ...

Purpose: To confirm the feasibility and estimate the efficacy of methotrexate (MTX), teniposide, carmustine, and methylprednisolone (MBVP) chemotherapy combined with radiotherapy (RT) for patients ...

Deep learning based on preoperative MR to differentiate germinomas from nongerminomatous cell tumors. The efficacy of boron neutron capture therapy with folate receptor targeted novel boron carrier in ...

FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and ...

These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

– Updated Results from Phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab, to be Presented – – Pilot Study Results of Yescarta ® in Relapsed/Refractory Primary ...

Roche Holding AG RHHBY announced that the late-stage study evaluating its marketed drug, Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), for the treatment of relapsed or ...